[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100632512":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":28,"centralContacts":33,"locations":44,"responsibleParty":76,"collaborators":38,"id":79,"slug":80,"hasResults":81,"nctId":82,"briefTitle":83,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":81,"sex":86,"minAge":87,"maxAge":38,"enrollmentInfo":88,"targetDuration":38,"studyType":91,"phases":92,"briefSummary":94,"conditions":95,"keywords":100,"overallStatus":47,"whyStopped":38,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":114},{"fullName":5,"class":6},"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"CVVHD (Historical Control)","ACTIVE_COMPARATOR","Historical control cohort of patients treated with continuous venovenous hemodialysis (CVVHD) with regional citrate anticoagulation between 2019 and 2021 in the intensive care unit (ICU) of Hospital de la Santa Creu i Sant Pau.",[13],"Procedure: continuous renal replacement therapy",{"label":15,"type":16,"description":17,"interventionNames":18},"CVVHDF with Post-Filter Replacement","EXPERIMENTAL","Prospective cohort of patients treated with continuous venovenous hemodiafiltration (CVVHDF) with post-filter replacement under regional citrate anticoagulation. Patients admitted to the ICU of Hospital de la Santa Creu i Sant Pau from November 2024 onwards who require continuous renal replacement therapy (CRRT) will be included.",[13],[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"PROCEDURE","continuous renal replacement therapy","Continuous renal replacement therapy (CRRT) using regional citrate anticoagulation. Treatment modalities include continuous venovenous hemodialysis (CVVHD) and continuous venovenous hemodiafiltration (CVVHDF) with post-filter replacement, depending on study group assignment.",[9,15],[26,27],"CVVHDF","CVVHD",[29],{"name":30,"affiliation":31,"role":32},"Alejandra Espinosa Guerrero, Clinical Operations Head","Fundació de Gestió Sanitarària de l'Hospital de la Santa Creu i Sant Pau de Barcelona","STUDY_DIRECTOR",[34,40],{"name":35,"role":36,"phone":37,"phoneExt":38,"email":39},"Ana Jiménez Valenzuela, Nurse","CONTACT","+34935537796",null,"ajimenezva@santpau.cat",{"name":30,"role":36,"phone":41,"phoneExt":42,"email":43},"+34 935537796","7796","uicec@santpau.cat",[45],{"facility":46,"status":47,"city":48,"state":48,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"Hospital de la Santa Creu i Sant Pau","RECRUITING","Barcelona","08041","Spain","ES",{"type":53,"coordinates":54},"Point",[55,56],2.15899,41.38879,{"lat":56,"lon":55},[59,61,63,65,68,70,72,74],{"name":35,"role":36,"phone":60,"phoneExt":38,"email":39},"+34662172345",{"name":62,"role":36,"phone":37,"phoneExt":42,"email":43},"Alejandra Espinosa, Clinical Operations Head",{"name":35,"role":64,"phone":38,"phoneExt":38,"email":38},"PRINCIPAL_INVESTIGATOR",{"name":66,"role":67,"phone":38,"phoneExt":38,"email":38},"Antoni Jordi Betbesé Roig, Clinical Head of the ICU","SUB_INVESTIGATOR",{"name":69,"role":67,"phone":38,"phoneExt":38,"email":38},"Almudena Mateos Dávila, Doctor of Nursing and Health",{"name":71,"role":67,"phone":38,"phoneExt":38,"email":38},"Ariadna González Ybarra, Nurse",{"name":73,"role":67,"phone":38,"phoneExt":38,"email":38},"Ariadna Pérez Rodriguez, Nurse",{"name":75,"role":67,"phone":38,"phoneExt":38,"email":38},"Víctor Guerrero Cruz, Nurse",{"type":64,"investigatorFullName":77,"investigatorTitle":78,"investigatorAffiliation":5,"oldNameTitle":38,"oldOrganization":38},"Ana Jiménez Valenzuela","Principal Investigator","100632512","validation-of-a-regional-citrate-anticoagulation-protocol-in-critically-ill-patients-on-continuous-renal-replacement-therapy-100632512",false,"NCT07514650","Validation of a Regional Citrate Anticoagulation Protocol in Critically Ill Patients on Continuous Renal Replacement Therapy","CRRT","Inclusion Criteria\n\n* Age ≥18 years\n* Admission to the intensive care unit (ICU)\n* Diagnosis of acute kidney injury (AKI) requiring continuous renal replacement therapy (CRRT)\n* Use of regional citrate anticoagulation during CRRT Exclusion Criteria\n* Known allergy or intolerance to citrate\n* Contraindications to citrate anticoagulation (e.g., severe liver failure or severe metabolic disorders affecting citrate metabolism)\n* Pregnancy or breastfeeding","ALL","18 Years",{"count":89,"type":90},43,"ESTIMATED","INTERVENTIONAL",[93],"NA","The objective of this study is to evaluate the effectiveness of a modified continuous renal replacement therapy (CRRT) protocol in maintaining electrolyte balance in adult patients with acute kidney injury (AKI) admitted to the intensive care unit (ICU).\n\nThe study assesses whether the use of continuous venovenous hemodiafiltration (CVVHDF) with post-filter replacement under citrate anticoagulation reduces electrolyte losses and the need for electrolyte supplementation compared with standard dialytic CRRT.\n\nParticipants receiving standard CRRT will be compared with those treated with the modified protocol.\n\nThe duration of participation corresponds to the period during which CRRT is required. Data collection will cease once CRRT is discontinued.",[96,97,98,99],"Acute Kidney Injury","ICU Patients","Continuous Renal Replacement Therapy (CRRT)","Electrolytes",[101,96,102,103,104,99],"Regional Citrate Anticoagulation","ICU patients","Continuous Renal Replacement Therapy","Diluted citrate","2026-04-01",{"date":107,"type":108},"2026-04-07","ACTUAL",{"date":110,"type":108},"2024-11-24",{"date":112,"type":90},"2026-11",{"name":5,"class":6},1]